Soligenix, Inc. (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases

Founded 1987

Princeton, United States 27 employees Post Ipo Equity Total: $55.97M Biopharma, Biotechnology +1

Soligenix: A late-stage biopharmaceutical company, was founded in 1987. The company's slogan emphasizes its focus on developing and commercializing products to treat rare diseases. Soligenix's Specialized BioTherapeutics business segment is currently working on HyBryte™ (SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), with plans for regulatory approval and commercialization in the U.S. Additionally, the company is developing expansion programs for synthetic hypericin into psoriasis, an innate defense regulator technology for inflammatory diseases, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention and treatment of gastrointestinal disorders, including pediatric Crohn's disease. In the Public Health Solutions business segment, Soligenix is actively developing RiVax®, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses, coronaviruses including COVID-19, and a therapeutic candidate for antibiotic-resistant and emerging infectious diseases. These programs have received support from government grants and contract funding. Notably, the company secured a $4.75M post-IPO equity investment on 18 April 2024. With a strong focus on addressing unmet medical needs, Soligenix is leveraging its expertise in biopharma, biotechnology, and healthcare from its headquarters in the United States. The company's diverse portfolio and government support in the development of crucial health solutions position it as a compelling investment opportunity in the biopharmaceutical industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	••••••	-		18 Apr 2024
Post-IPO Equity	••••••	-		05 May 2023
Post-IPO Debt	••••••	1		15 Nov 2022
Grant	••••••	1	•••• ••••	06 Sep 2022
Grant	••••••	2	•••• ••••	19 Apr 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

••••••

18 Apr 2024

Post-IPO Equity

••••••

05 May 2023

Post-IPO Debt

••••••

15 Nov 2022

Grant

••••••

•••• ••••

06 Sep 2022

Grant

••••••

•••• ••••

19 Apr 2022

FAQ About Soligenix, Inc.

We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases

Soligenix, Inc. was founded in 1987.

Soligenix, Inc. is headquartered in Princeton, United States.

Soligenix, Inc. operates in the following industries: Biopharma, Biotechnology, Health Care.

Soligenix, Inc. has approximately 27 employees.

Soligenix, Inc. has completed 15 funding rounds, raising a total of $55.97M. The latest funding stage is Post Ipo Equity.

Top alternatives and competitors to Soligenix, Inc. include United Biomedical, Inc. (UBI), 辽宁依生生物制药有限公司, SpyBiotech, Valneva, Visterra Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Soligenix, Inc. and United Biomedical, Inc. (UBI) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Soligenix, Inc.

General Information

Track Soligenix, Inc.

Discover More

About Soligenix, Inc.

Funding Rounds & Investors (15)

Soligenix, Inc. Alternatives & Competitors

FAQ About Soligenix, Inc.

Don't just browse. Track.